readthroughSign in
Nov 12, 2026Quarterly update

Parabilis reports Q3 2026 results, aligns with FDA on desmoid Phase 3 design

The company said it reached FDA alignment on a global Phase 3 trial for zolucatetide in desmoid tumors and reported $1.1 billion in cash as of September 30, 2026.

Parabilis Medicines reported financial results and business updates for the quarter ended September 30, 2026, on November 12, 2026. The company said it reached alignment with the FDA on a global Phase 3 trial design and plans to initiate the randomized, double-blind "PEDESTAL" Phase 3 registrational trial in desmoid tumors in the first half of 2027, with topline results expected in 2029.1

At the ESMO Congress 2026, Parabilis presented data from a June 22, 2026 cut of its ongoing Phase 1/2 trial showing an objective response rate of 72.2% (13/18) among patients evaluable at the 32-week landmark who received a starting dose of 450 mg or more, a disease control rate of 100% with no disease progression across 46 response-evaluable patients at that dose level, and no treatment discontinuations due to treatment-related adverse events among 76 patients evaluated for safety.1

The company also initiated a dose-ranging cohort in its ongoing Phase 1/2 trial to evaluate zolucatetide in patients with familial adenomatous polyposis, aiming to identify an optimal dose and regimen.1 Separately, Parabilis entered a clinical collaboration with Revolution Medicines under which Parabilis will sponsor and run a study pairing zolucatetide with RevMed's zoldonrasib, described as an investigational oral RAS(ON) G12D-selective covalent tri-complex inhibitor, and cetuximab, an EGFR inhibitor, for previously treated RAS G12D mutant microsatellite stable metastatic colorectal cancer, with RevMed providing zoldonrasib and the two companies splitting trial costs equally.1

On financials, the company reported cash, cash equivalents and marketable securities of $1.1 billion as of September 30, 2026, compared with $27.7 million at the end of 20251, which it said is expected to fund operations into 2030.1 Net loss for the quarter was $44.5 million, compared with $33.5 million in the prior-year period.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.